Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis

Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to ou...

Full description

Bibliographic Details
Main Authors: Naomi Onda, Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007114000586
_version_ 1817992330959912960
author Naomi Onda
Yosuke Tanaka
Mitsunori Hino
Akihiko Gemma
author_facet Naomi Onda
Yosuke Tanaka
Mitsunori Hino
Akihiko Gemma
author_sort Naomi Onda
collection DOAJ
description Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to our hospital due to aggravation of dyspnea and decreased oxygen saturation, as well as onset of orthopnea and rapidly progressing edema. The transthoracic echocardiography and right heart catheterization showed the mean pulmonary artery pressure was 39 mmHg and the mean pulmonary capillary wedge pressure was 9 mmHg. After various examinations, the diagnoses of pulmonary hypertension (PH) due to IPF and of congestive heart failure secondary to PH were established. Diuretic therapy was started, but the patient's condition showed poor improvement. Subsequent initiation of oral bosentan therapy led to improvement in symptoms and findings. At the follow-up assessment one year later her pulmonary function showed no significant changes and no apparent worsening of arterial blood gases, with evident improvement of PH, WHO functional class, maximum exercise tolerance on treadmill exercise testing, right heart catheterization, and transthoracic echocardiography. This report describes a case of successful treatment with bosentan for severe pulmonary hypertension in a patient with idiopathic pulmonary fibrosis. We also present a review of the literature on treatment of pulmonary hypertension in patients with chronic lung disease. Bosentan appears to be efficacious in some patients with pulmonary hypertension secondary to idiopathic interstitial pneumonitis.
first_indexed 2024-04-14T01:24:54Z
format Article
id doaj.art-eaccf4518321492ba737d3dcca29cc32
institution Directory Open Access Journal
issn 2213-0071
language English
last_indexed 2024-04-14T01:24:54Z
publishDate 2015-01-01
publisher Elsevier
record_format Article
series Respiratory Medicine Case Reports
spelling doaj.art-eaccf4518321492ba737d3dcca29cc322022-12-22T02:20:29ZengElsevierRespiratory Medicine Case Reports2213-00712015-01-0114C192310.1016/j.rmcr.2014.11.008Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosisNaomi Onda0Yosuke Tanaka1Mitsunori Hino2Akihiko Gemma3Nippon Medical School, Chiba Hokusoh Hospital, Respiratory Disease Center, JapanNippon Medical School, Chiba Hokusoh Hospital, Respiratory Disease Center, JapanNippon Medical School, Chiba Hokusoh Hospital, Respiratory Disease Center, JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanPulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to our hospital due to aggravation of dyspnea and decreased oxygen saturation, as well as onset of orthopnea and rapidly progressing edema. The transthoracic echocardiography and right heart catheterization showed the mean pulmonary artery pressure was 39 mmHg and the mean pulmonary capillary wedge pressure was 9 mmHg. After various examinations, the diagnoses of pulmonary hypertension (PH) due to IPF and of congestive heart failure secondary to PH were established. Diuretic therapy was started, but the patient's condition showed poor improvement. Subsequent initiation of oral bosentan therapy led to improvement in symptoms and findings. At the follow-up assessment one year later her pulmonary function showed no significant changes and no apparent worsening of arterial blood gases, with evident improvement of PH, WHO functional class, maximum exercise tolerance on treadmill exercise testing, right heart catheterization, and transthoracic echocardiography. This report describes a case of successful treatment with bosentan for severe pulmonary hypertension in a patient with idiopathic pulmonary fibrosis. We also present a review of the literature on treatment of pulmonary hypertension in patients with chronic lung disease. Bosentan appears to be efficacious in some patients with pulmonary hypertension secondary to idiopathic interstitial pneumonitis.http://www.sciencedirect.com/science/article/pii/S2213007114000586BosentanEndothelin antagonistIdiopathic pulmonary fibrosisPulmonary hypertensionRespiratory failure
spellingShingle Naomi Onda
Yosuke Tanaka
Mitsunori Hino
Akihiko Gemma
Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
Respiratory Medicine Case Reports
Bosentan
Endothelin antagonist
Idiopathic pulmonary fibrosis
Pulmonary hypertension
Respiratory failure
title Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
title_full Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
title_fullStr Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
title_full_unstemmed Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
title_short Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
title_sort bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
topic Bosentan
Endothelin antagonist
Idiopathic pulmonary fibrosis
Pulmonary hypertension
Respiratory failure
url http://www.sciencedirect.com/science/article/pii/S2213007114000586
work_keys_str_mv AT naomionda bosentanforpulmonaryhypertensionsecondarytoidiopathicpulmonaryfibrosis
AT yosuketanaka bosentanforpulmonaryhypertensionsecondarytoidiopathicpulmonaryfibrosis
AT mitsunorihino bosentanforpulmonaryhypertensionsecondarytoidiopathicpulmonaryfibrosis
AT akihikogemma bosentanforpulmonaryhypertensionsecondarytoidiopathicpulmonaryfibrosis